TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02447042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with crystalloids
Description: Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with crystalloids
Description: Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with crystalloids
Description: Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pmsf-arm
Description: Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pmsf-arm
Description: Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pmsf-arm
Description: Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pmsf-arm
Description: Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
Study: NCT02150317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE+Sorafenib
Description: TACE followed by Sorafenib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE alone
Study: NCT03068481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03378128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
Study: NCT00655044

Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
Study: NCT01927224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (4 x 30 mg tablet)
Description: 120 mg single dose as four 30 mg tablets after a high fat, high calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (4 x 30 mg tablet)
Description: 120 mg single dose as four 30 mg tablets after a high fat, high calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)
Description: 120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (120 mg tablet)
Description: 120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
Study: NCT05422196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Description: Addition of platelet-rich fibrin into the cleft site.
Study: NCT00838890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cdc7-inhibitor (BMS-863233)
Description: Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
Study: NCT03103048

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
Study: NCT00838890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cdc7-inhibitor (BMS-863233)
Description: Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
Study: NCT03570645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group
Description: combination of ropivacaine and dexmedetomidine 100 ug every time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone group
Description: combination of ropivacaine and dexamethasone 10mg every time

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control group
Description: block with only ropivacaine
Study: NCT04359654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalation Solution [Pulmozyme]
Description: Nebulised Dornase alfa 2.5mg bd for 7 days
Study: NCT02420392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
Study: NCT03103048

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
Study: NCT04031937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychomotor assessment
Description: the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
Study: NCT03305445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (1mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3mg/kg)
Study: NCT06165146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.
Study: NCT06165146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study: NCT02596919

Intervention type: OTHER
Group type: OTHER
Intervention: photography
Description: photography of meibomian glands
Study: NCT01408394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ecopipam immediate release form
Description: Tablet containing 100 mg of the immediate release form of ecopipam
Study: NCT03990610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer
Description: Undergo vascularized lymph node transfer
Study: NCT06050343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin® Regular
Description: subcutaneous injection at a dose of 0.3 IU / kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin® Regular
Description: subcutaneous injection at a dose of 0.3 IU / kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin® R
Description: subcutaneous injection at a dose of 0.3 IU / kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin® R
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study: NCT01408394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg controlled release form
Description: This is the 90 mg controlled release form
Study: NCT00216086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid
Study: NCT01408394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180 mg controlled release form
Description: This is the 180 mg controlled release capsule
Study: NCT00216086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 200 mg/m2 IV, day 1
Study: NCT06522633

Intervention type: DRUG
Group type: OTHER
Intervention: The intervention involves the discontinuation of the opioid.
Description: Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
Study: NCT02045147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 1a Low Cognition, Low Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 2a Low Cognition, High Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 3a Normal Cognition, Low Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 4a Normal Cognition, High Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
Study: NCT02955758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV, 200mg fixed dose, every 3 weeks
Study: NCT04182724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Apatinib and Nab-paclitaxel
Description: Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
Study: NCT04061525

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration
Description: Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
Study: NCT03583684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Program (PRT-P)
Description: The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
Study: NCT03307616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03004287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given by mouth at bedtime: days 1-4 of Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by vein: days 1-4 (continuous infusion) of Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Given by vein: days 1-4 (continuous infusion) of Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein: days 1-4 (continuous infusion) of Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given by vein: days 1-4 (continuous infusion) of Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by vein: days -4 - -1 of Transplant(s)
Study: NCT04597788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein supplemented very low calorie diet program
Description: Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss.
Study: NCT03004287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: day 0 of Transplant(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
Study: NCT04308707

Intervention type: OTHER
Intervention: Breaking bad news skills
Description: Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.

Intervention type: OTHER
Intervention: Breaking bad news skills
Description: Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
Study: NCT00700830

Intervention type: DRUG
Intervention: insulin detemir
Description: Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
Study: NCT00955526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: 20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: 40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets once daily for 12 weeks
Study: NCT03036254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBOT intervention
Description: HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HBOT intervention
Description: HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff.
Study: NCT00718913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
Study: NCT04354116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Description: Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Protraction
Description: Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Protraction
Description: Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).